Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27224424 | 0.89 | — | — | |
| SCHEMBL27224420 | 0.84 | — | — | |
| SCHEMBL357991 | 0.80 | MAPK1 (0.36) | MAPK1 | |
| SCHEMBL29860057 | 0.78 | PREP (0.33) | — | |
| SCHEMBL14269373 | 0.73 | PREP (0.31) | — | |
| SCHEMBL266354 | 0.71 | — | — | |
| SCHEMBL4886317 | 0.70 | — | — | |
| SCHEMBL14726723 | 0.70 | LMNA (0.35) | — | |
| SCHEMBL16409741 | 0.69 | HTR2C (0.33) | MAPK1 | |
| SCHEMBL24925904 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084092-A1 | ANNULATED PYRIDAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2025-03-13 | — | — | US | disclosed |
| CN-118234711-A | Cyclopyridazine compounds | 尼科治疗有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-4375274-A1 | ANNULATED PYRIDAZINE COMPOUND | Nico Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2013010453-A1 | CHEMOKING RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084092-A1 | ANNULATED PYRIDAZINE COMPOUND | NLRP3, NLRP1, PYCARD | MAPK1 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.